Evaluating the Use of Levofloxacin to Prevent MDR Tuberculosis Transmission in Children
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on January 29th, 2025
|
Young children under the age of 5 are particularly vulnerable to developing symptomatic diseases following exposure to Mycobacterium tuberculosis. In cases of multidrug-resistant (MDR) tuberculosis, managing the infection becomes significantly more expensive and complex. The current approach to controlling the spread of MDR tuberculosis in young children involves household contact tracing from individuals recently diagnosed with the infection. A recent study published in the New England Journal of Medicine explored the use of levofloxacin to prevent the transmission of MDR bacteria in young children.
The study was conducted in South Africa, involving 922 children under the age of 5 who lived in households with at least one adult diagnosed with MDR tuberculosis within the past 6 months. Prior to enrollment, the children were screened for tuberculosis through chest radiography and microbiological analysis of respiratory samples. The median age of the children was 2.8 years, and 93.8% had previously received the BCG vaccine. Participants were randomly assigned to receive daily treatment with either a placebo or levofloxacin, with a dosage ranging from 15 to 20 mg per kilogram of body weight, capped at 750 mg. After 48 weeks, the analysis showed that the incidence of tuberculosis was lower in the levofloxacin group, although this difference was not statistically significant. The researchers suggested that the lack of significant findings could be due to the implementation of the Xpert MTB/RIF assay for diagnosis and the use of bedaquiline/linezolid for treating tuberculosis in South Africa at the time of the trial, which may have reduced the infectiousness of the bacteria.
The study was conducted in South Africa, involving 922 children under the age of 5 who lived in households with at least one adult diagnosed with MDR tuberculosis within the past 6 months. Prior to enrollment, the children were screened for tuberculosis through chest radiography and microbiological analysis of respiratory samples. The median age of the children was 2.8 years, and 93.8% had previously received the BCG vaccine. Participants were randomly assigned to receive daily treatment with either a placebo or levofloxacin, with a dosage ranging from 15 to 20 mg per kilogram of body weight, capped at 750 mg. After 48 weeks, the analysis showed that the incidence of tuberculosis was lower in the levofloxacin group, although this difference was not statistically significant. The researchers suggested that the lack of significant findings could be due to the implementation of the Xpert MTB/RIF assay for diagnosis and the use of bedaquiline/linezolid for treating tuberculosis in South Africa at the time of the trial, which may have reduced the infectiousness of the bacteria.